Mathias Baedeker - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Mathias Baedeker

Showing results (11-20 of 14) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 14 results.

Nature Reviews. Drug Discovery|February 3, 2017

Market watch: Value of 2016 FDA drug approvals: reversion to the mean?Ulrik Schulze, Michael Ringel, Valery Panier, et al.

Nature Reviews. Drug Discovery|April 23, 2014

R&D productivity: on the comeback trailUlrik Schulze, Mathias Baedeker, Yen Ting Chen, et al.

Nature Reviews. Drug Discovery|April 18, 2020

Breaking Eroom's LawMichael S Ringel, Jack W Scannell, Mathias Baedeker, et al.

Nature Reviews. Drug Discovery|January 13, 2023

2022 FDA approval number dips: a COVID-19 hangover?Mathias Baedeker, Michael S Ringel, Clemens C Möller, et al.

Pageof 2

Search research articles

Showing results (11-20 of 14) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 14 results.

Nature Reviews. Drug Discovery|February 3, 2017

Market watch: Value of 2016 FDA drug approvals: reversion to the mean?Ulrik Schulze, Michael Ringel, Valery Panier, et al.

Nature Reviews. Drug Discovery|April 23, 2014

R&D productivity: on the comeback trailUlrik Schulze, Mathias Baedeker, Yen Ting Chen, et al.

Nature Reviews. Drug Discovery|April 18, 2020

Breaking Eroom's LawMichael S Ringel, Jack W Scannell, Mathias Baedeker, et al.

Nature Reviews. Drug Discovery|January 13, 2023

2022 FDA approval number dips: a COVID-19 hangover?Mathias Baedeker, Michael S Ringel, Clemens C Möller, et al.

Pageof 2